Study S000279

A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06882961 ADMINISTRATION IN ADULTS WITH OBESITY

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT04707313
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 628
Start: 2021-01-29
Primary completion: 2023-09-13
Lead sponsor: Pfizer
Conditions: Obesity
Interventions: DRUG:Placebo (Cohorts 1 and 2); DRUG:PF-06882961 (Cohorts 1 and 2); DRUG:Placebo (Cohort 3); DRUG:PF-06882961 (Cohort 3)
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: EUDRACT_NUMBER:2020-001312-19

Registered primary outcomes

Cohorts 1 and 2: Percent Change From Baseline in Body Weight at End of Treatment at Week 26 [Baseline, Week 26]
Cohort 3: Percent Change From Baseline in Body Weight at End of Treatment at Week 32 [Baseline, Week 32]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0005921	Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study. Buckeridge C, Diabetes, obesity & metabolism	2025	Randomized trial	PMID 40539310 DOI	cites ClinicalTrials.gov:NCT04707313; registry reference DERIVED:40539310